Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | CPA1 | P15085 | 2/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207891 | 1.00 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL8028251 | 1.00 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL18560091 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL2034664 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL288609 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL203222 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL43380 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL43381 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL203221 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 | |
| SCHEMBL2034259 | 0.85 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201642-A1 | Bioactive Compounds | BLUNT JOHN | 2011-08-18 | — | — | US | disclosed |
| EP-2352746-A1 | BIOACTIVE COMPOUNDS | Universiti Teknologi Mara (MY) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010062159-A1 | BIOACTIVE COMPOUNDS | UNIVERSITI TEKNOLOGI MARA (MY) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201642-A1 | Bioactive Compounds | TPI1, XPO1, GDI1 | ALDH1A1 1421/4885L3MBTL1 4709/4885MME 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.